As shown in Fig. 5B, in contrast to the PBS-treated control mice which showed typical though variable pathological changes of colitis, including mucosal thickening, crypt elongation, inflammatory cell infiltration as well as crypt abscesses, no or minimal such changes were observed in all of the five BregIL-33-treated IL-10−/− mice. Here, IL10 is linked to colitis.